Table 2.
Medication use and disease characteristics of the individuals with AAD.
| Type of GC | All, n = 52 | Females, n = 33 | Males, n = 19 | P-value (female vs. male) |
|---|---|---|---|---|
| IR-HC (n) | 43 | 27 | 16 | |
| GC dose (mg/m2/day)a (mean (SD)) | 13.3 (3.4) | 13.3 (3.5) | 13.4 (3.4) | 0.811 |
| Doses/day (mean (SD)) | 2.6 (0.7) | 2.6 (0.7) | 2.6 (0.6) | 0.885 |
| MR-HC (n) | 9 | 6 | 3 | |
| GC dose (mg/m2/day)b (mean (SD)) | 12.3 (2.8) | 11.2 (2.2) | 14.4 (2.9) | 0.187 |
| Doses/day (mean (SD)) | 1.4 (0.7)c | 1.3 (0.5) | 1.7 (1.2) | 0.673 |
| 9-α fludrocortisone, median dose in mg (range)d | 0.1 (0.05–0.25) | 0.1 (0.05–0.25) | 0.1 (0.05–0.20) | 0.117 |
| Disease characteristics | ||||
| Age at AAD diagnosis (years) (mean (SD)) median range |
22.7 (6.3) 22 13–34 |
23.5 (6.2) 23 13–34 |
21.7 (6.6) 19 14–34 |
0.344 |
| AAD duration (years) (mean (SD)) median range |
9.6 (5.0) 9.8 2.5–25 |
9.4 (4.0) 9.8 2.5–18 |
10.1 (6.6) 9.0 2.8–25 |
0.668 |
| Number of adrenal crises (mean (SD)) median range |
3.4 (5.3) 1 0–25 |
4 (5.6) 2 0–25 |
2.5 (4.6) 1 0–20 |
0.296 |
| Hypothyroidism | 42.3% | 48.5% | 31.6% | 0.370 |
| Depression and ADHD | ||||
| ADHD diagnosis | 1 | 1 | 0 | 1 |
| SSRI use (yes) | 7 | 7 | 0 | 0.083 |
P-values indicate comparisons between male and female patients, Wilcoxon tests for nonparametric data were used, and chi-square tests for the relative number of participants with an ADHD diagnosis and using antidepressants. From those on IR-HC replacement therapy, 1 patient had only one dose per day, 19 had 2 doses per day, 20 had 3 doses per day, and 3 individuals had 4 doses per day. ADHD, attention deficit hyperactivity disorder; SSRI, selective serotonin reuptake inhibitor.
aTotal IR-HC dose per day in mg/m2 of body surface (total mg/sqrt (cm*kg/3,600)).
bTotal IR-HC equivalence dose per day in mg/m2 of body surface (total mg/sqrt(cm*kg/3,600)).
cSome participants on MR-HC take additional IR-HC doses on demand.
d34 Individuals were on a dose of 0.1 mg of Florinef (9-α fludrocortisone), to replace mineralocorticoids, 5 individuals were on 0.05 mg, 1 patient on 0.075, 1 on 0.2 mg, 1 on 0.25 mg, and 1 patient did not take Florinef.